Squamous Cell Cancer Clinical Trial
Official title:
Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase I B/II Trial
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
This is a non-randomized phase I B/II trial enrolling 43 patients with recurrent and/or
metastatic SCCHN who are not candidates for surgical salvage or definitive radiation.
Subjects will receive Cetuximab and sorafenib until disease progression. Cetuximab will be
given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
Sorafenib will be given 200 mg twice daily oral, continuous dosing to the 6 patients in
cohort 1. If less than 3 patients experience dose limiting toxicities (DLT) at the 200mg BID
dose, then 6 patients will be accrued at the 400mg BID dose level and toxicities will again
be examined. Sorafenib will be given 400 mg twice daily oral, continuous dosing to the
patients in cohort 2. One cycle equals 28 days. Tumor assessment will be performed every 8
weeks. Treatment continues until disease progression or unacceptable side effects.
Participating subjects will be asked to take part in an optional correlative study to
provide previously archived diagnostic or therapeutic tumor samples obtained during the
course of their routine medical care for their cancer of the head/neck. The optional tissue
repository project is Duke University Health System (DUHS) Institutional Review Board (IRB)
approved (eIRB # 11138 / "Tissue Acquisition Protocol for Analysis of Effects of Novel
Chemotherapeutic Compounds). Subjects will be asked to sign a separate consent form to
participate in the tissue collection study.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
| Completed |
NCT00705016 -
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01721525 -
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
|
Phase 1 | |
| Completed |
NCT01016769 -
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00661427 -
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Completed |
NCT00382031 -
Zalutumumab in Patients With Non-curable Head and Neck Cancer
|
Phase 3 | |
| Recruiting |
NCT04391049 -
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
|
Phase 1 | |
| Recruiting |
NCT05932511 -
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
|
Early Phase 1 | |
| Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00542308 -
Zalutumumab in Non-curable Patients With SCCHN
|
Phase 2 | |
| Completed |
NCT00485485 -
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Terminated |
NCT02376699 -
Safety Study of SEA-CD40 in Cancer Patients
|
Phase 1 | |
| Completed |
NCT00255476 -
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
|
Phase 2 | |
| Recruiting |
NCT03935893 -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
|
Phase 2 | |
| Terminated |
NCT00401401 -
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00559351 -
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
|
Phase 3 | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03509467 -
Using MC1R Genotype to Impact Melanoma Risk Behavior
|
N/A | |
| Completed |
NCT01384708 -
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
|
Phase 0 |